Biology & drug discovery · London, UK · founded 2023

Latent Labs: who founded it, who funds it

Latent Labs is a London AI drug discovery lab founded in 2023 by Simon Kohl, who came from DeepMind. What it is building: protein and antibody design with a wet lab, from an AlphaFold co-developer. It has raised $50M in disclosed rounds, most recently a Series A of $50M in February 2025, led by Radical Ventures and Sofinnova Partners. It sells access through an API.

APIBiology & drug discovery

Website

Founders: Simon Kohl (ex-Google DeepMind)
Founders from: ex-Google DeepMind
Location: London, UK (Europe)
Valuation: ·
Raised: $50M disclosed
Investors: Radical Ventures lead, Sofinnova Partners lead
What ships: API

Rounds

Date	Round	Amount	Valuation	Lead	Source
Feb 11, 2025	Series A	$50M	·	Radical Ventures, Sofinnova Partners	neolabs.fyi

Sources

neolabs.fyi neolabs.fyi

News

Sep 9, 2026
Latent Labs Number of Employees 2026 | Employee Count & Headcount Data

AnalysisRevelio LabsLatent Labs
Jul 21, 2026
Latent Labs Unveils Latent-Y: A Revolutionary Drug Design Tool for Researchers

ProductSynBioBetaLatent Labs
Jul 15, 2026
Latent Labs Launches Latent-Y to Researchers Worldwide — With Free Daily Access and On-Demand Credits for Larger Campaigns

AnalysisBusiness WireLatent Labs
May 1, 2026
Inside Latent Labs’ Autonomous Drug Design Engine

AnalysisSynBioBetaLatent Labs
Mar 23, 2026
Latent-Y: The Autonomous AI Agent for Drug Design at Scale

AnalysisBusiness WireLatent Labs
Dec 16, 2025
Latent Labs Announces Latent-X2: AI-Generated Antibodies With Drug-Like Developability and Low Ex Vivo Immunogenicity

AnalysisLelezardLatent Labs

Investors who back other labs here

Radical Ventures also: World Labs, Decart, Generalist AI, Prime Intellect

Same research area

Chai Discovery $3.8B · San Francisco, US
Merge Labs $850M · San Francisco, US
EvolutionaryScale · · New York, US
Isomorphic Labs · · London, UK
Xaira Therapeutics · · South San Francisco, US